ReviewEndocrine2022
Thyroid disorders and cardiovascular manifestations: an update.
Review in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases.Nature genetics · 2026Pooled it
- Effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide levels: A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Article
- Thyroid function and outcomes in heart failure with mildly reduced ejection fraction: insights from a large, retrospective registry.Endocrine · 2026Article
- Article
- Navigating thyroid hormone signaling in liver fibrosis: mechanisms and clinical implications.Journal of endocrinological investigation · 2026Review
- Thyroid disorders in idiopathic inflammatory myopathies: prevalence and related clinical scenarios.BMC endocrine disorders · 2026Article
- Psychological Symptoms, Nutritional Risk, and Quality of Life in Hemodialysis Patients: A Structural Equation Modeling Study.International journal of environmental research and public health · 2026Article
- Aescin and rutin mitigate hyperthyroidism-induced multisystem dysfunction via antioxidant and anti-inflammatory mechanisms in a rat model.Scientific reports · 2026Article
- The study on serum oxidized low-density lipoprotein and homocysteine as cardiovascular risk markers in subclinical hypothyroidism patients.Frontiers in endocrinology · 2026Article
- Multidimensional Mechanisms of Hypertension and Advances in Diagnosis and Integrated TCM-Based Treatment: A Review.International journal of general medicine · 2026Review
- FT3 Levels and Systemic Inflammation: Evidence From a Population-Based NHANES Analysis.Mediators of inflammation · 2026Article
- Thyroid storm-induced cardiovascular complications and modalities of therapy: Up-to-date review.World journal of critical care medicine · 2025Review
- Article
- Heart Failure in Polycystic Ovarian Syndrome and Hypothyroidism: A Retrospective Large Database Analysis.Cureus · 2025Article
- Hypothyroidism: playing the cardiometabolic risk concerto.Thyroid research · 2025Review
- Iodinated contrast media (ICM)-induced thyroid dysfunction: a review of potential mechanisms and clinical management.Clinical and experimental medicine · 2025Review
- The Effect of Thyroid Lobe Volume on the Common Carotid Artery Blood Flow in Thyroidectomy Position.Journal of clinical medicine · 2025Article
- THRA1/PGC-1α/SIRT3 pathway regulates oxidative stress and is implicated in hypertension of maternal hypothyroid rat offspring.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Associations between indicators of lipid and glucose metabolism and hypothyroidism.Lipids in health and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide, representing a major health, social, and economic issue. Thyroid disorders are very common and affect >10% of the adult population in total. The aim of this review is to describe the physiologic role of thyroid hormones on cardiovascular system, to present cardiovascular manifestations in patients with thyroid disorders, emphasizing in molecular mechanisms and biochemical pathways, and to summarize current knowledge of treatment options. Thyroid hormone receptors are located both in myocardium and vessels, and changes in their concentrations affect cardiovascular function. Hyperthyroidism or hypothyroidism, both clinical and subclinical, without the indicated therapeutical management, may contribute to the progression of CVD. According to recent studies, even middle changes in thyroid hormones levels increase cardiovascular mortality from 20% to 80%. In more details, thyroid disorders seem to have serious effects on the cardiovascular system via plenty mechanisms, including dyslipidemia, hypertension, systolic and diastolic myocardial dysfunction, as well endothelial dysfunction. On top of clinical thyroid disorders management, current therapeutics focus on younger patients with subclinical hypothyroidism and elderly patients with subclinical hyperthyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.